Athira Pharma (ATHA)
US Market

Athira Pharma Stock Price & Analysis


ATHA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.53 - $14.22
Previous Close$2.94
Average Volume (3M)255.59K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$220.96M
Total Debt (Recent Filing)$1.99M
Price to Earnings (P/E)-1.4
Next EarningsMar 23, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.17
Shares Outstanding37,829,305
Standard Deviation0.26
10 Day Avg. Volume279,287
30 Day Avg. Volume255,587
Price to Book (P/B)0.47
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside340.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Athira Pharma’s price range in the past 12 months?
Athira Pharma lowest stock price was $2.53 and its highest was $14.22 in the past 12 months.
    What is Athira Pharma’s market cap?
    Currently, no data Available
    When is Athira Pharma’s upcoming earnings report date?
    Athira Pharma’s upcoming earnings report date is Mar 23, 2023 which is in 106 days.
      How were Athira Pharma’s earnings last quarter?
      Athira Pharma released its earnings results on Nov 10, 2022. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.638 by $0.108.
        Is Athira Pharma overvalued?
        According to Wall Street analysts Athira Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Athira Pharma pay dividends?
          Athira Pharma does not currently pay dividends.
          What is Athira Pharma’s EPS estimate?
          Athira Pharma’s EPS estimate is -$0.65.
            How many shares outstanding does Athira Pharma have?
            Athira Pharma has 37,829,304 shares outstanding.
              What happened to Athira Pharma’s price movement after its last earnings report?
              Athira Pharma reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.638. Following the earnings report the stock price went up 8.389%.
                Which hedge fund is a major shareholder of Athira Pharma?
                Among the largest hedge funds holding Athira Pharma’s share is Perceptive Advisors LLC. It holds Athira Pharma’s shares valued at 14M.


                  Athira Pharma Stock Smart Score

                  The Athira Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Athira Pharma

                  Athira Pharma Inc is a bio-technology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Verrica Pharmaceuticals
                  Trevi Therapeutics
                  Lyra Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis